Culver Annie L, Ockene Ira S, Balasubramanian Raji, Olendzki Barbara C, Sepavich Deidre M, Wactawski-Wende Jean, Manson Joann E, Qiao Yongxia, Liu Simin, Merriam Philip A, Rahilly-Tierny Catherine, Thomas Fridtjof, Berger Jeffrey S, Ockene Judith K, Curb J David, Ma Yunsheng
Rochester Methodist Hospital, MayoClinic, Rochester, MN, USA.
Arch Intern Med. 2012 Jan 23;172(2):144-52. doi: 10.1001/archinternmed.2011.625. Epub 2012 Jan 9.
This study investigates whether the incidence of new-onset diabetes mellitus (DM) is associated with statin use among postmenopausal women participating in the Women's Health Initiative (WHI).
The WHI recruited 161,808 postmenopausal women aged 50 to 79 years at 40 clinical centers across the United States from 1993 to 1998 with ongoing follow-up. The current analysis includes data through 2005. Statin use was captured at enrollment and year 3. Incident DM status was determined annually from enrollment. Cox proportional hazards models were used to estimate the risk of DM by statin use, with adjustments for propensity score and other potential confounding factors. Subgroup analyses by race/ethnicity, obesity status, and age group were conducted to uncover effect modification.
This investigation included 153,840 women without DM and no missing data at baseline. At baseline, 7.04% reported taking statin medication. There were 10,242 incident cases of self-reported DM over 1,004,466 person-years of follow-up. Statin use at baseline was associated with an increased risk of DM (hazard ratio [HR], 1.71; 95% CI, 1.61-1.83). This association remained after adjusting for other potential confounders (multivariate-adjusted HR, 1.48; 95% CI, 1.38-1.59) and was observed for all types of statin medications. Subset analyses evaluating the association of self-reported DM with longitudinal measures of statin use in 125,575 women confirmed these findings.
Statin medication use in postmenopausal women is associated with an increased risk for DM. This may be a medication class effect. Further study by statin type and dose may reveal varying risk levels for new-onset DM in this population.
本研究调查了参与妇女健康倡议(WHI)的绝经后女性中新发糖尿病(DM)的发病率是否与他汀类药物的使用有关。
WHI从1993年至1998年在美国40个临床中心招募了161,808名年龄在50至79岁的绝经后女性,并进行持续随访。当前分析纳入了截至2005年的数据。在入组时和第3年记录他汀类药物的使用情况。从入组开始每年确定新发DM状态。使用Cox比例风险模型通过他汀类药物的使用情况估计DM风险,并对倾向得分和其他潜在混杂因素进行调整。按种族/族裔、肥胖状态和年龄组进行亚组分析以发现效应修饰。
本调查纳入了153,840名无DM且基线时无缺失数据的女性。在基线时,7.04%的女性报告正在服用他汀类药物。在1,004,466人年的随访期间,有10,242例自我报告的DM新发病例。基线时使用他汀类药物与DM风险增加相关(风险比[HR],1.71;95%置信区间[CI],1.61 - 1.83)。在调整其他潜在混杂因素后,这种关联仍然存在(多变量调整后的HR,1.48;95%CI,1.38 - 1.59),并且在所有类型的他汀类药物中均观察到。对125,575名女性中自我报告的DM与他汀类药物使用的纵向测量之间关联的子集分析证实了这些发现。
绝经后女性使用他汀类药物与DM风险增加相关。这可能是药物类别效应。按他汀类药物类型和剂量进行的进一步研究可能揭示该人群中新发DM的不同风险水平。